Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience
ConclusionThe REP index is an independent prognostic factor for OS and PFS in patients with advanced HCC treated with regorafenib.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Italy Health | Liver | Liver Cancer | Liver Disease | South Korea Health | Statistics | Study | Urology & Nephrology